Phenylalanine-binding MIP

About MipSalus

MipSalus is a private, preclinical-stage biotech company pioneering the therapeutic application of Molecular Imprinted Polymers (MIPs). Its core technology platform creates synthetic, antibody-like binding sites within polymers to selectively capture and remove target molecules, such as amino acids, from the gut in a non-systemic manner. The company's initial focus is on developing a first-in-class oral treatment for all variants of Hyperphenylalaninemia (HPA), including Phenylketonuria (PKU). MipSalus operates with a lean team, is funded by founders, private investors, and public grants, and follows a strategy of achieving proof-of-concept before seeking partnerships for clinical development and commercialization.

Therapeutic Areas